Clinical trials: Age Related Maculopathy
Age Related Macular Degeneration
Study of WA-NG (NG-IMT) Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration
The purpose of this study is to evaluate the safety of the updated Model WA-NG telescope prosthesis (hereafter WA-NG telescope), an injectable telescope device, in patients with bilateral moderate to profound central vision…
- Trial name
- NCT04468373
- Testing
- WA-NG (NG-IMT) Telescope Prothesis
- Where
- 2 sites in Ireland, Spain
- Volunteers
- 9 people
- Sponsor
- VisionCare, Inc.
Age Related Macular Degeneration
HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device
The overall objective of this two arm randomized clinical trial (RCT) is to determine if home monitoring using the comprehensive visual field and telemedicine solution based on the ForeseeHome device in AREDS2 improves detection…
- Trial name
- AREDS (NCT01103505)
- Testing
- ForeseeHome AMD Monitoring Device
- Where
- 38 sites in United States
- Volunteers
- 1,520 people
- Sponsor
- Notal Vision Ltd.
Geographic Atrophy, Stargardt Disease
Phase 1 Study of C.001 in Retinal Degeneration
This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.
- Conditions
- Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
- Trial name
- NCT07594236
- Testing
- Injection
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cellio Therapeutics Inc
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
This study is a prospective, non-interventional, multicenter, open-label study in nAMD and DME patients being treated with brolucizumab according to the EU SmPC.
- Trial name
- BLUE SKY (NCT04543331)
- Testing
- brolucizumab
- Where
- 41 sites in Germany
- Volunteers
- 572 people
- Sponsor
- Novartis Pharmaceuticals
Geographic Atrophy
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This Phase 1, open-label, multicenter study will investigate the safety and tolerability of RO7171009 following single and multiple intravitreal (ITV) administrations in patients with GA secondary to AMD.
- Trial name
- NCT03295877
- Testing
- RO7171009
- Where
- 13 sites in United States
- Volunteers
- 28 people
- Sponsor
- Genentech, Inc.
Adults With Neovascular Age-related Macular Degeneration
This is a 96-week, Multicenter Study in Patients With Neovascular AMD That Evaluates OCUL101 for Efficacy, Safety, Durability, and Pharmacokinetics, Comparing it With Another Treatment. The Study Will be Conducted in Two Parts, Part A and Part B.
Oculgen has begun a study of an investigational drug called OCUL101 as a possible treatment for neovascular AMD. An investigational drug is one that has not been approved by regulatory agencies, such as the Food and Drug…
- Trial name
- STAT (NCT07520318)
- Testing
- bispecific anti-VEGF and anti-complement
- Volunteers
- 255 people
- Sponsor
- Shenzhen Oculgen Biomedical Technology Co., Ltd.
Low Vision, Age Related Macular Degeneration
Early Feasibility Study Using IOPCL MAG to Improve Near Vision in ARMD Subjects
This early feasibility study aims to improve near vision in subjects 55 years or older who have a clinical diagnosis of Age-Related Macular Degeneration.
- Trial name
- NCT04984590
- Testing
- IOPCL AMD MAG
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- OnPoint Vision Inc
Polypoidal Chorodial Vasculopathy, Age Related Macular Degeneration
IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD
This study will evaluate the efficacy of IRay treatment in patients with Polypoidal Choroidal Vasculopathy (PCV)secondary to AMD as determined by the change in the proportion of lesion activity and lesion size at 12 months.
- Trial name
- NCT01516294
- Testing
- Iray
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Oraya Therapeutics, Inc.
Dry Age-related Macular Degeneration
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
- Trial name
- NCT04065490
- Testing
- Valeda Light Delivery System
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- LumiThera, Inc.
Neovascular Age-related Macular Degeneration
Effectiveness of Brolucizumab in Pre-treated Patients With nAMD in the Real-world Setting
The study is a prospective and retrospective, observational, single-arm, non-randomized cohort study of ocular treatment with intravitreal injections of brolucizumab in nAMD patients.
- Trial name
- NCT05266495
- Testing
- Brolucizumab
- Where
- United Arab Emirates
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Mobile Clinic - a Cross-sectional Epidemiological Survey
The aim of the study is to find out prevalence of aged-related macular degeneration (AMD) in Slovak Republic. The outcome of the project will be epidemiology survey, prevalence of wet form of AMD in relation to demographic data…
- Trial name
- NCT02055612
- Where
- Slovakia
- Volunteers
- 3,278 people, healthy volunteers welcome
- Sponsor
- Novartis Slovakia, s.r.o.
Macular Degeneration
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)
This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration.
- Trial name
- VIEW 2 (NCT00637377)
- Testing
- Ranibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
- Where
- 189 sites in Argentina, Australia and 24 more
- Volunteers
- 1,240 people
- Sponsor
- Bayer
Age-related Macular Degeneration (AMD)
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
The purpose of this first-in-human study is to evaluate the safety and tolerability of single ascending doses of LMG324 to determine the maximum tolerated dose (MTD) in neovascular age-related macular degeneration (nvAMD)…
- Trial name
- NCT02398500
- Testing
- LMG324, Ranibizumab 0.5 mg
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Alcon Research
Macular Degeneration
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis® in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).
- Trial name
- XPLORE (NCT03805100)
- Testing
- Ranibizumab
- Where
- 102 sites in United States, Bulgaria and 13 more
- Volunteers
- 582 people
- Sponsor
- Xbrane Biopharma AB
Wet Age-related Macular Degeneration
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of QL1207 compared to Eylea® in subjects with wet AMD.
- Trial name
- NCT05345236
- Testing
- Aflibercept
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Macular Degeneration
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)
- Trial name
- NCT02540954
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 71 sites in Austria, Canada and 12 more
- Volunteers
- 336 people
- Sponsor
- Bayer
Macular Degeneration
Efficacy of Electrical Micro-current Retinal Stimulation for Treatment of Dry Age-related Macular Degeneration
Hypothesis: external electrical stimulation of the retina with low level electrical currents improves visual acuity in subjects with age-related dry macular degeneration.
- Trial name
- NCT01600300
- Testing
- Tesmac
- Volunteers
- 40 people
- Sponsor
- Acuity Medical International, Inc.
Geographic Atrophy, Age-Related Macular Degeneration
Geographic Atrophy Treatment Evaluation
The purpose of this study was to evaluate the safety and efficacy of AL-8309B Ophthalmic Solution versus Vehicle administered as a topical ocular drop for the treatment for geographic atrophy (GA) secondary to age-related macular…
- Trial name
- GATE (NCT00890097)
- Testing
- AL-8309B Ophthalmic Solution, AL-8309B Vehicle
- Volunteers
- 772 people
- Sponsor
- Alcon Research
Geographic Atrophy, Macular Degeneration
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a…
- Trial name
- NCT06779773
- Testing
- Avacincaptad pegol (ACP)
- Where
- 58 sites in United States
- Volunteers
- 488 people
- Sponsor
- Astellas Pharma Global Development, Inc.